Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...

Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 20.4% following news that two top FDA officials overseeing cell and gene therapies have been placed on administrative leave.

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company announced the completion ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Capricor Therapeutics announced that the U.S. FDA has accepted its Biologics License Application (BLA) for deramiocel, aimed at treating cardiomyopathy in patients with Duchenne muscular dystrophy ...

Capricor Therapeutics, a biotechnology company focused on developing cell and exosome-based therapies for rare diseases, has announced its participation in several upcoming investor conferences.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food ...